Pneumonia Market 2024-2034
                     Pneumonia 
Market Research 
Report 2024-
2034
ABOUT IMARC
International Market Analysis Research and 
Consulting Group is a leading adviser on 
management strategy and market research 
worldwide. We partner with clients in all regions and 
industry verticals to identify their highest-value 
opportunities, address their most critical challenges, 
and transform their businesses.
IMARC’s information products include major market, 
scientific, economic and technological developments 
for business leaders in pharmaceutical, industrial, 
and high technology organizations. Market forecasts 
and industry analysis for biotechnology, advanced 
materials, chemicals, food and beverage, travel and 
tourism, nanotechnology and novel processing 
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable 
insight into the dynamics of companies and markets 
with close cooperation at all levels of the client 
organization. This ensures that our clients achieve2 
unmatchable competitive advantage, build more 
proficient organizations, and secure lasting results.
Report Description and Highlights
Pneumonia Market Report Overview:
• Report Attribute Details
• Base Year                   2023
• Forecast Years 2024-2034
• Historical Years 2018-2023
• Market Growth (2024-2034)  5.32%
The report offers a comprehensive analysis of the Pneumonia market in the United States, EU5 (including Germany, Spain, Italy, France, and 
the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the 
proportion of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance 
of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in 
the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved 
in the Pneumonia market.
3
Report Description and Highlights
Market Overview:
The 7 major pneumonia markets are expected to exhibit a CAGR of 5.32% during 2024-2034. Pneumonia is an 
infection that causes swelling and fluid or pus buildup in the alveoli (air sacs) of one or both lungs. The 
pneumonia market is undergoing substantial growth and transformation, propelled by a multitude of factors. 
Pneumonia stands as a key contributor to morbidity and mortality worldwide, affecting individuals of all age 
groups. The rising incidence of pneumonia, especially among vulnerable populations like the elderly and young 
children, serves as a primary catalyst for market expansion. The introduction of effective pneumonia vaccines, 
such as the pneumococcal conjugate vaccine (PCV) and the influenza vaccine, has played a prominent role in 
alleviating the burden of pneumonia. Government-sponsored vaccination initiatives and public awareness 
campaigns have further accelerated vaccine adoption rates. Rapid advancements in diagnostic technologies, 
including molecular testing and imaging modalities like chest X-rays and CT scans, have substantially 
enhanced the precision and speed of pneumonia diagnosis. Early and accurate diagnosis is pivotal for effective 
treatment. In response to the growing concern of antibiotic resistance, pharmaceutical companies are 
investing in the development of novel antibiotics and antimicrobial agents to combat the causative pathogens 
4
of pneumonia, including bacteria, viruses, and fungi.
Report Description and Highlights
The COVID-19 pandemic has expedited the adoption of telemedicine and remote monitoring in healthcare. 
These technologies enable healthcare professionals to remotely manage pneumonia patients, reducing the risk 
of transmission and enhancing patient access to care. Robust research into pneumonia’s pathophysiology and 
treatment options has led to the discovery of innovative therapies and medication guidelines. Continued 
investment in research remains a driving force behind innovation in pneumonia management. Governments 
across the world have recognized the paramount importance of pneumonia prevention and treatment. They 
have implemented policies and funding programs aimed at improving healthcare infrastructure, raising 
awareness, and ensuring equitable access to healthcare services. Patient advocacy groups and organizations 
are playing a pivotal role in increasing awareness and advocating for improved prevention measures for 
pneumonia. These efforts are expected to further bolster market growth in the years to come.
Request a Sample Report: https://www.imarcgroup.com/chemotherapy-induced-pain-market/requestsample
5
Report Description and Highlights
What is included in the report segmentation?
The report covers the following aspects:
Report Period:
• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
Countries Included:
• United States
• Germany
• France
6
Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country:
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Pneumonia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Pneumonia market
• Reimbursement scenario in the market
• In-market and pipeline drugs
This report also provides a detailed analysis of the current Pneumonia marketed drugs and late-
stage pipeline drugs.
7
Report Description and Highlights
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
View Report TOC, Figures and Tables: https://www.imarcgroup.com/pneumonia-market
8
Report Description and Highlights
Competitive Landscape With Key Players:
The competitive landscape of the Pneumonia market has been studied in the report with the detailed profiles 
of the key players operating in the market.
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: 
https://www.imarcgroup.com/request?type=report&id=8133&flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as 
a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research 
worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, 
address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for 
business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and 
industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and 
tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. 9
Report Description and Highlights
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: [email protected]
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com/
1
0
Key Questions Answered in the Report
1. How has the Pneumonia market performed so far and how will it perform in the coming years?
2. What are the markets shares of various therapeutic segments in 2023 and how are they expected to 
perform till 2034?
3. What was the country-wise size of the Pneumonia market across the seven major markets in 2023 and 
what will it look like in 2034?
4. What is the growth rate of the Pneumonia market across the seven major markets and what will be the 
expected growth over the next ten years?
5. What are the key unmet needs in the market?
11
Table of 
Contents
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
13
Table of Contents
4 Pneumonia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Pneumonia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
    
Click here to visit the complete table of content with list of figures and tables: 
https://www.imarcgroup.com/pneumonia-market/toc
14
Partial List Of Our Clients
15
OUR CLIENTS
16
Disclaimer
© 2024 IMARC All Rights Reserved 
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of 
International Market Analysis Research and Consulting (IMARC). No part of this publication may be 
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be 
used in any form or by and means graphic electronic or mechanical, including photocopying, recording, 
taping or by information storage or retrieval, or by any other form, without the express consent of 
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion 
have been based on information and sources believed to be accurate and reliable at the time of 
publishing. International Market Analysis Research and Consulting makes no representation of warranty 
of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability 
whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this 
publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International 
Market Analysis Research and Consulting. All other trademarks used in this publication are registered 
1
trademarks of their respective companies. 7